Posted inBusiness Exelixis falls 8% on abstract for colorectal cancer candidate zanzalintinib Posted by admin January 22, 2025No Comments [ad_1] Exelixis falls 8% on abstract for colorectal cancer candidate zanzalintinib [ad_2] admin View All Posts Post navigation Previous Post Coinbase seeks ruling that crypto trades on its platform aren't securitiesNext PostGE Aerospace Q4 2024 earnings preview: All eyes on annual margin, delivery projections